Abstract
Natural variants of human papillomavirus (HPV) are classified into lineages and sublineages based upon whole-genome sequence, but the impact of diversity on protein function is unclear. We investigated the susceptibility of 3-8 representative pseudovirus variants of HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58 to neutralization by nonavalent vaccine (Gardasil®9) sera. Many variants demonstrated significant differences in neutralization sensitivity from their consensus A/A1 variant but these were of a low magnitude. HPV52 D and HPV58 C variants exhibited >4-fold reduced sensitivities compared to their consensus A/A1 variant and should be considered distinct serotypes with respect to nonavalent vaccine-induced immunity.
| Original language | English |
|---|---|
| Pages (from-to) | 1940-1945 |
| Number of pages | 6 |
| Journal | Journal of Infectious Diseases |
| Volume | 220 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 6 Nov 2019 |
Bibliographical note
Funding Information:Financial support. This work was supported by Public Health England; the National Cancer Institute, National Institutes of Health (contract number HHSN261200800001E); and by the Bill and Melinda Gates Foundation to develop and distribute qualified standardized reagents for human papillomavirus research as a service to be made available to the extramural research community.
Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Keywords
- antibody
- human papillomavirus
- lineage
- neutralization
- vaccine
- variant
